<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503345</url>
  </required_header>
  <id_info>
    <org_study_id>0000649</org_study_id>
    <nct_id>NCT02503345</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones</brief_title>
  <official_title>A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of different
      doses of ALLN 177 for reducing urinary oxalate excretion in patients with secondary
      hyperoxaluria and recurrent kidney stones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo controlled study to evaluate the
      efficacy of ALLN 177 compared with placebo in reducing the urinary excretion of oxalate in
      subjects with secondary hyperoxaluria and kidney stones. ALLN-177 is an orally administered
      form of oxalate decarboxylase. The goal of therapy with ALLN-177 is to reduce urinary oxalate
      excretion by decreasing the absorption of oxalate from the gastrointestinal tract.

      Eligible subjects will be randomized to 7 days of treatment with a dose ALLN-177 or placebo
      and following a washout period, crossed over to an alternate treatment. Urinary oxalate
      excretion will be assessed by 24-hr urine collections throughout the study.

      The study allows for up to 60 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean urinary oxalate excretion (mg/24 h) following treatment</measure>
    <time_frame>on 7 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean urinary oxalate excretion (mg/24 h)</measure>
    <time_frame>on 7 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Secondary Hyperoxaluria</condition>
  <condition>Nephrolithiasis</condition>
  <condition>Kidney Stones</condition>
  <condition>Hyperoxaluria</condition>
  <condition>Dietary Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules (1, 2 or 5) PO TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALLN-177 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALLN-177 1,500 units/meal PO TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALLN-177 mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALLN-177 3,000 units/meal PO TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALLN-177 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALLN-177 7,500 units/meal PO TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLN-177 low dose</intervention_name>
    <description>ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day</description>
    <arm_group_label>ALLN-177 low dose</arm_group_label>
    <other_name>Oxalate decarboxylase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLN-177 mid dose</intervention_name>
    <description>ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day</description>
    <arm_group_label>ALLN-177 mid dose</arm_group_label>
    <other_name>Oxalate decarboxylase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLN-177 high dose</intervention_name>
    <description>ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day</description>
    <arm_group_label>ALLN-177 high dose</arm_group_label>
    <other_name>Oxalate decarboxylase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 1, 2 or 5 capsules with meals PO 3 times per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of enteric or idiopathic hyperoxaluria and at least one kidney stone within
             the past 2 years

          -  Hyperoxaluria at screening

          -  May be taking drugs for the prevention of stone disease

        Exclusion Criteria:

          -  Hyperuricosuria

          -  Glomerular filtration rate &lt; 55 mL/min/1.73m2

          -  Hypercalcemia or hypothyroidism

          -  Obstructive uropathy, chronic urosepsis, renal failure, renal tubular acidosis,
             primary hyperparathyroidism, primary hyperoxaluria, pure uric acid and cystine stones,
             and/or medullary sponge kidney

          -  Treatment with cholestyramine

          -  Average daily dietary intake of oxalate &lt;75 mg per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annamaria Kausz, MD MS</last_name>
    <role>Study Director</role>
    <affiliation>VP Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tower Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Urological Associates</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Nephrology And Hypertension</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Feinberg School Of Medicine - Urology Department</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Physicians Urology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Urology</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11694</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Health System/The Arthur Miller Institute for Urology</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University - Division Of Nephrology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic-Urology</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Clinical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center - Urology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Stones</keyword>
  <keyword>Nephrolithiasis</keyword>
  <keyword>Urine Oxalate</keyword>
  <keyword>Hyperoxaluria</keyword>
  <keyword>Enteric Hyperoxaluria</keyword>
  <keyword>Idiopathic Hyperoxaluria</keyword>
  <keyword>Urological Diseases</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Dietary Oxalate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

